Director/PDMR Shareholding
Summary by AI BETAClose X
Haleon plc: Director/PDMR Shareholding
24 September 2026: Haleon plc (the “Company” or “Haleon”) (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 24 September 2026, the Company was notified of the following transactions as detailed below.
|
1
|
Details of the issuer, emission allowance market participant
|
||||
|
a)
|
Name
|
Haleon plc |
|||
|
b) |
LEI
|
549300PSB3WWEODCUP19 |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the person discharging managerial responsibilities / person closely associated (“PCA”) |
||||
|
a)
|
PDMR/PCA
|
PDMR |
|||
|
b)
|
Name
|
Dawn Allen |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of Instrument
Identification code
|
Share
GB00BMX86B70
|
|||
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares as a result of dividend reinvestment
|
|||
|
c)
|
Currency, Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£3.44631 |
2,317.19703 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
N/A |
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
22 September 2026
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1
|
Details of the issuer, emission allowance market participant
|
|||||||||||
|
a)
|
Name
|
Haleon plc |
||||||||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
||||||||||
|
2
|
Reason for the notification
|
|||||||||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||||||||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
||||||||||
|
3
|
Details of the person discharging managerial responsibilities / person closely associated (“PCA”) |
|||||||||||
|
a)
|
PDMR/PCA |
PDMR |
||||||||||
|
b)
|
Name
|
Brian McNamara |
||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||||||
|
a)
|
Description of Instrument
Identification code
|
Share
GB00BMX86B70
|
||||||||||
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares as a result of dividend reinvestment
|
||||||||||
|
c)
|
Currency, Price(s) and volume(s) |
|
|
|
|
|||||||
|
|
|
|
Price(s) |
Volume(s) |
|
|||||||
|
|
|
|
£3.44631 |
12,208.83196 |
|
|||||||
|
|
|
|
|
|
|
|||||||
|
d)
|
Aggregated information |
N/A |
||||||||||
|
|
|
|||||||||||
|
- Aggregated volume |
|
|||||||||||
|
|
|
|||||||||||
|
- Price |
|
|||||||||||
|
|
|
|||||||||||
|
e)
|
Date of the transaction
|
22 September 2026
|
||||||||||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||||||
|
a)
|
Description of Instrument
Identification code
|
Share
US4055521003
|
||||||||||
|
b)
|
Nature of the transaction
|
Acquisition of ADSs as a result of dividend reinvestment
|
||||||||||
|
c)
|
Currency, Price(s) and volume(s) |
|
|
|
|
|||||||
|
|
|
Price(s) |
Volume(s) |
|
||||||||
|
|
|
$9.3801 |
2,139.05113 |
|
||||||||
|
|
|
|
|
|
||||||||
|
d)
|
Aggregated information |
N/A |
||||||||||
|
|
|
|||||||||||
|
- Aggregated volume |
|
|||||||||||
|
|
|
|||||||||||
|
- Price |
|
|||||||||||
|
|
|
|||||||||||
|
e)
|
Date of the transaction
|
22 September 2026 |
||||||||||
|
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
||||||||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 hours ago Savannah Energy
- 3 hours ago Buccaneer Energy PLC
- 4 hours ago Savannah Energy
- 4 hours ago Carclo
- 4 hours ago Schroder Japan Growth Fund